Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

C4 THERAPEUTICS, INC.

(CCCC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 3000 Value Index

06/25/2021 | 12:00am EDT

C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 3000 Value Index


© S&P Capital IQ 2021
All news about C4 THERAPEUTICS, INC.
09/17INSIDER SELL : C4 Therapeutics
MT
09/15Certain Common Stock of C4 Therapeutics, Inc. are subject to a Lock-Up Agreem..
CI
09/15Certain Stock Options of C4 Therapeutics, Inc. are subject to a Lock-Up Agree..
CI
09/14INSIDER SELL : C4 Therapeutics
MT
08/12C4 THERAPEUTICS' : Q2 Loss Narrows, Revenue Grows; Secures Orphan Drug Designati..
MT
08/11C4 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
08/11C4 THERAPEUTICS : Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a ..
PU
08/11C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulatio..
AQ
08/11C4 THERAPEUTICS : Reports Recent Business Highlights and Second Quarter 2021 Fin..
AQ
08/11C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Tre..
GL
More news
Analyst Recommendations on C4 THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 31,1 M - -
Net income 2021 -104 M - -
Net cash 2021 378 M - -
P/E ratio 2021 -21,9x
Yield 2021 -
Capitalization 2 420 M 2 420 M -
EV / Sales 2021 65,6x
EV / Sales 2022 67,9x
Nbr of Employees 99
Free-Float 87,2%
Chart C4 THERAPEUTICS, INC.
Duration : Period :
C4 Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends C4 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 49,95 $
Average target price 61,33 $
Spread / Average Target 22,8%
EPS Revisions
Managers and Directors
Andrew J. Hirsch President, Chief Executive Officer & Director
Lauren White Treasurer, Chief Financial & Accounting Officer
Marc A. Cohen Executive Chairman
Adam S. Crystal Chief Medical Officer
Stewart Fisher Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
C4 THERAPEUTICS, INC.50.77%2 420
MODERNA, INC.311.65%177 867
LONZA GROUP AG36.36%62 278
IQVIA HOLDINGS INC.43.07%49 407
CELLTRION, INC.-23.26%31 021
SEAGEN INC.-10.81%27 940